Tivic Health Systems, Inc. Annual Report: A Year of Change

I am writing this guide to help you understand how Tivic Health performed this year. My goal is to explain their complex financial filings in plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Tivic Health has hit the "reset" button. They are moving away from their old consumer health business—specifically the "Clearup" sinus relief device—to focus entirely on drug development. Their biggest move this year was a partnership with Statera Biopharma to develop treatments for serious conditions like Acute Radiation Syndrome. Tivic has shifted from a gadget manufacturer to an early-stage biotech firm focused on clinical trials and licensing.

2. Financial performance

The company is in a rebuilding phase. For the year ending December 31, 2024, Tivic reported $0.3 million in revenue, down from $0.8 million in 2023. This drop reflects the wind-down of their old product line. Expenses remained high due to the strategic pivot, leading to a loss of about $8.5 million. With only $0.5 million in cash left at year-end, the company is burning through its remaining money to fund this transition.

3. Major wins and challenges

• The Big Pivot: The Statera license agreement is the heart of the company’s future. It gives Tivic exclusive rights to develop Statera’s drug candidates. Tivic must now hit specific clinical milestones to keep these rights.
• The Hurdle: Shutting down the old business while building a drug pipeline is expensive and distracting. The company had to fire staff and sell off inventory, which created one-time costs that impacted their bottom line.

4. Financial health: The "Dilution" Warning

This is the most important part for you. To keep the lights on, Tivic raised money throughout 2024 and 2025 by issuing new shares and convertible notes.

What this means for you: Every time they issue new shares, they print more "tickets" to the company. This reduces your ownership percentage, meaning your "slice of the pie" gets smaller. They also issued warrants, which are coupons that allow holders to buy stock at fixed prices. If the stock price rises, these warrants will likely be used, flooding the market with new shares. This creates a "ceiling" that makes it hard for the stock price to grow.

5. Key risks

• Dilution: The constant issuance of new stock is a major concern. The company relies on financing that converts debt into shares at discounted rates, making it difficult for your investment to grow.
• Execution Risk: Moving from selling devices to developing drugs is a massive challenge. There is no guarantee these licenses will lead to an FDA-approved product.
• Financial Fragility: The company depends on outside funding to survive. With very little cash left, they face a high risk of running out of money if they don't secure more capital.

6. Future outlook

Tivic is now a start-up. Their future depends entirely on the Statera partnership and the FDA clinical trial process. If they hit their goals, they may attract new interest. If they miss, or run out of cash, the company faces severe financial pressure and a potential loss of value for shareholders.

---

Note: This is a high-risk, speculative situation. The company has abandoned its previous path and is now a "bet" on a new drug development pipeline. Before investing, consider whether you are comfortable with the high likelihood of further share dilution and the long, uncertain timeline of clinical drug development.